Aura Biosciences, Inc. (AURA)
| Market Cap | 442.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -106.19M |
| Shares Out | 64.20M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,925 |
| Open | 6.95 |
| Previous Close | 6.96 |
| Day's Range | 6.85 - 7.06 |
| 52-Week Range | 4.35 - 7.68 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 19.00 (+175.76%) |
| Earnings Date | May 14, 2026 |
About AURA
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AURA stock is "Strong Buy." The 12-month stock price target is $19.0, which is an increase of 175.76% from the latest price.
News
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-mon...
Aura Biosciences Transcript: Leerink Global Healthcare Conference 2026
A novel virus-like drug conjugate platform is advancing in phase III for early choroidal melanoma, with additional studies in ocular and bladder cancers. The addressable market could reach 66,000 patients, and key data readouts are expected this year and in Q4 2027.
Aura Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Strong progress in ocular oncology and bladder cancer programs, with phase III ocular melanoma trial on track for top-line data in Q4 2027 and mid-year data expected for bladder cancer. Market opportunities are expanding with ultra-orphan pricing and new indications, while safety and vision preservation remain key differentiators.
Aura Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference
A novel drug platform is advancing in late-stage trials for early choroidal melanoma and bladder cancer, with a strong safety profile and unique frontline positioning. Key milestones include phase III enrollment completion in 2026 and multiple proof-of-concept readouts in 2026.
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference
BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ funct...
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint
Aura Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A novel virus-like drug conjugate platform is advancing through late-stage trials in ocular and bladder cancers, targeting high unmet needs with strong early efficacy and safety data. Upcoming milestones include phase 3 enrollment completion and data readouts, with cash runway into 2027.
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ func...
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)
Aura Biosciences Transcript: 6th Annual Oncology Innovation Summit
Late-stage clinical programs are advancing in ocular melanoma and bladder cancer, with strong efficacy, safety, and immune activation data supporting further development. Key data readouts are expected between late 2026 and early 2027, and rare disease pricing strategies are being pursued.
Aura Biosciences Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
The VDC platform enables dual-selective, tumor-agnostic therapy with strong early data in ocular and bladder cancers. Phase 3 trials are underway globally, with rapid uptake expected in ocular oncology and expansion into other solid tumors considered. Recent fundraising extends operational runway into 2027.
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve org...
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve org...
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025
Aura Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025
A novel virus-like drug conjugate platform is advancing in phase III for uveal melanoma, showing strong efficacy and safety, with expansion into bladder cancer and other solid tumors. Key data readouts are expected within six months, and the company is fully funded through 2026.
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ functi...
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ func...
Aura Biosciences Transcript: Status Update
Bel-sar's dual mechanism offers a novel, well-tolerated approach for NMIBC, showing strong early efficacy and immune activation. The updated phase 1B2 trial will optimize dosing and expand patient cohorts, with potential to disrupt current standards and reduce healthcare burden.
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect
Aura Biosciences Transcript: Leerink Global Healthcare Conference 2025
A novel virus-like drug conjugate platform is showing promise in early-stage ocular melanoma, achieving high tumor control and vision preservation, with a Phase III trial underway. The approach is expanding into bladder cancer, aiming for a paradigm shift in front-line therapy.
Aura Biosciences Transcript: TD Cowen 45th Annual Healthcare Conference
Advancing virus-like drug conjugates in ocular oncology and bladder cancer, with late-stage trials showing strong efficacy and organ preservation. Regulatory milestones achieved, with new data and study designs to be presented soon. Focus remains on early, local treatment to shift paradigms in cancer care.
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 ...
Aura Biosciences Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference
Bel-sar, a virus-like drug conjugate, shows strong efficacy in early-stage ocular melanoma with 80% local cure and 90% vision preservation, and promising results in bladder cancer. Phase 3 ocular study is global, with BLA submission targeted for 2026 and approval in 2027.
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical an...